John Jesitus is a medical writer based in Westminster, CO.
Research program strives to improve patient care
December 3rd 2019In this article, we highlight the Johns Hopkins Cutaneous Translational Research Program (CTReP), which integrates academic and clinical resources to help illuminate concepts and mechanisms that may help patients with a variety of dermatologic concerns.
JAK inhibitors offer multiple applications
March 21st 2019Unlike prior generations of dermatologic drugs, Janus kinase (JAK) inhibitors show potential for treating numerous dermatologic indications. Brett King, M.D., Ph.D. explored what this class of drug has to offer in his presentation during AAD earlier this month.
Atopic dermatitis treatments move beyond one-size-fits-all
March 21st 2019In the future, atopic dermatitis (AD) may need to be targeted with different drugs and tailored for different AD populations, particularly if initial treatment targeting all phenotypes fails, says Emma Guttman-Yassky, M.D., Ph.D.
Future of skin resurfacing lies in drug delivery, postprocedural care
March 6th 2019Fractional ablative and nonablative lasers cover a wide variety of indications, but skin tightening results often require adjunctive treatment modalities and postprocedural regimens remain a puzzle, says Susan Van Dyke, M.D.
Standards are high for JAK inhibitors in psoriasis
March 2nd 2019While this new class of medications still has a role in treating psoriasis, this physician says the standard for both their efficacy and safety is very high because of the existing, already very effective systemic therapies available today.
In-office Rx dispensing fills care gap
February 25th 2019Although prescribers who provide in-office dispensing must satisfy applicable state and other requirements, a recent ruling against Allergan's attempt to shut down Prescriber's Choice appears to pave the way for expansion of these services, according to Wm. Philip Werschler, M.D.